The project uses a mouse model, human cells, and patient samples to determine whether Spy1 and related proteins provide a signature to identify triple negative breast cancer patients who will respond to specific treatments. The project also addresses whether targeting Spy1 represents a valuable therapeutic direction for patients with this form of aggressive breast cancer.